EUVIMEDEUVIMED entdecken
Crossref

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

Takafumi Yanagisawa iD, Kenichi Hata, Shintaro Narita, Shingo Hatakeyama, Keiichiro Mori, Yuji Yata, Takayuki Sano, Takashi Otsuka, Shuhei Hara, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya iD und 7 weitere

The Prostate · 2023

DOI: 10.1002/pros.24488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Takafumi Yanagisawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high‐risk metastatic hormone‐sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real‐world clinical practice setting.

Methods

The records of 336 patients who harbored de novo high‐risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC ( n = 109) or ABI ( n = 227) were retrospectively analyzed. Overall survival (OS), cancer‐specific survival (CSS), progression‐free survival (PFS), including time to castration‐resistant prostate cancer (CRPC), time to 2nd‐line progression (PFS2), and 2nd‐ and 3rd‐line PFS, were compared. We used one‐to‐two propensity score matching to minimize the confounders. The differential efficacy of 2nd‐line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest.

Results

After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3‐year OS and CSS for DOC versus ABI were 76.2% versus 75.1% ( p = 0.8) and 78.2% versus 78.6% ( p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd‐line PFS (14 vs. 4 months, p < 0.001) and 3rd‐line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd‐line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd‐line therapy (both 3 months, p = 0.8).

Conclusions

ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high‐risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd‐line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansDocetaxelAndrogen AntagonistsRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsHormonesTreatment OutcomeAndrostenes

Stichwörter der Autor:innen

abirateronedocetaxelhigh-riskmetastatic hormone-sensitive prostate cancersequential therapy

Substanzen

DocetaxelAndrogen AntagonistsHormonesabirateroneAndrostenes

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Atsugi City Hospital, Kanagawa, Japan.
  • Department of Urology, Akita University School of Medicine, Akita, Japan.
  • Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

ORCID-Profile: Takafumi Yanagisawa, Wataru Fukuokaya, Jun Miki

Zitieren

APA

Yanagisawa, T., Hata, K., Narita, S., Hatakeyama, S., Mori, K., Yata, Y., Sano, T., Otsuka, T., Hara, S., Miyajima, K., Enei, Y., Fukuokaya, W., Nakazono, M., Matsukawa, A., Miki, J., Habuchi, T., Ohyama, C., Shariat, S. F., & Kimura, T. (2023). Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. The Prostate. https://doi.org/10.1002/pros.24488

Vancouver

Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, et al. Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. The Prostate. 2023. doi:10.1002/pros.24488

BibTeX
@article{Yanagisawa2023,
  author = {Yanagisawa, Takafumi and Hata, Kenichi and Narita, Shintaro and Hatakeyama, Shingo and Mori, Keiichiro and Yata, Yuji and Sano, Takayuki and Otsuka, Takashi and Hara, Shuhei and Miyajima, Keiichiro and Enei, Yuki and Fukuokaya, Wataru and Nakazono, Minoru and Matsukawa, Akihiro and Miki, Jun and Habuchi, Tomonori and Ohyama, Chikara and Shariat, Shahrokh F and Kimura, Takahiro},
  title = {Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24488}
}
Kostenlos starten →